Aptamer revenues climb as York biotech delivers first licensing income

York-based Aptamer Group has reported a year of accelerating commercial progress after increasing revenues by 25%, expanding its sales pipeline by more than half and generating its first licensing income.

The AIM-listed biotechnology business expects to report revenue of approximately £1.5m for the year ended 30 June 2026, up from £1.2m the previous year, as demand for its Optimer® binders continued to grow across pharmaceutical and life sciences customers.

click here or login below...